MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program
Tripping on ibogaine can last over 24 hours, and it’s not always pleasant. But the wide range of benefits could make it worthwhile.
MINDCURE (MCUR) hopes so at least. The company filed a provisional patent for synthetic ibogaine mixtures to treat various central nervous system disorders like:
- Addiction
- Traumatic brain injury
- Anxiety disorders
- Chronic pain such as migraines and cluster headaches
The company aims to be a global supplier of synthetic ibogaine for research purposes and expects to have supply available by the end of Q2 this year.
